Cancer BiologybioRxiv
XPA tumor variants lead to defects in NER that sensitize cells to cisplatin
A. M. Blee, K. S. Gallagher, H.-S. Kim…·W. J. Chazin
This study identifies XPA tumor variants that impair NER, increasing cisplatin sensitivity, and provides mechanistic insights for variant effect prediction.
DOI 10.1093/narcan/zcae013